SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

The community is buzzing around ImmunityBio (IBRX) as founder Dr. Patrick Soon-Shiong appears in highly anticipated prime-time interviews to discuss breakthrough cancer treatments, with investors actively debating the potential for a significant short squeeze and an impactful business update next week that could challenge traditional pharma.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community rallies around the approaching 4/20, emphasizing a long-term "culture coin" vision for the cannabis ecosystem, even as discussions arise regarding its sustainability versus pump-and-dump characteristics.

Vanguard Group, Inc. - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF ($VTI) is generating significant discussion as a bellwether for the U.S. market, with investors observing strong inflows and its proximity to all-time highs. The community is weighing these positive signals against prevailing political and economic uncertainties, prompting ongoing debate about diversification and market direction.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

Applied Optoelectronics is surging following a strong earnings beat and upbeat guidance for AI/data center demand for its 400G and 800G transceivers, alongside significant analyst price target upgrades. The rally is fueled by short-squeeze momentum and optimism for future growth, though community discussion also reflects concerns over the company's valuation and a recent equity offering.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is trending sharply lower after missing Q4 earnings estimates and providing cautious 2026 guidance, igniting widespread investor frustration and calls for management accountability. Despite the dramatic price drop, some in the community view it as an overreaction and a potential buying opportunity, emphasizing the company's substantial order backlog and the growing demand for energy storage solutions.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending after a strong Q4 earnings beat, which included GAAP profitability and robust 2026 guidance driven by numerous new enterprise deals and impressive revenue growth. Despite these positive fundamentals, community sentiment expresses frustration over the stock's flat or declining price, with many blaming market manipulation by a significant short interest while long-term investors accumulate shares, confident in its AI leadership.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is witnessing intense trading and volatility, as the broader AI infrastructure sector reacts to a competitor's recent earnings, prompting strong debate among investors. The community is emphasizing NBIS's robust fundamentals and contrasting it with the perceived weaknesses of its peers.

Comcast Corp. engages in the provision of video, Internet, and phone services. It operates through the following segments: Residential Connectivity and Platforms, Business Services Connectivity, Media, Studios, and Theme Parks. The Residential Connectivity and Platforms segment consists of residential broadband and wireless services and Sky-branded entertainment television networks and advertising. The Business Service Connectivity segment offers broadband, wireline voice and wireless services through small to medium customers and large enterprises through the HFC network. The Media segment consists of NBCUniversal’s television and streaming platforms, including national, regional, and international cable networks. The Studios segment focuses on NBCUniversal’s film and television studio production and distribution operations. The Theme Parks segment operates Universal theme parks in Orlando, Florida, Hollywood, California, Osaka, Japan, and Beijing, China. The company was founded by Ralph Roberts in 1963 and is headquartered in Philadelphia, PA.

Comcast Corp - Ordinary Shares - Class A

Comcast Corp

Comcast is trending amid discussions surrounding its renewed bid to merge NBCUniversal with Warner Bros. Discovery, a strategic move generating debate about its potential to create a media powerhouse or add debt. The impending spin-off of Versant Media Group is also a key talking point, with investors anticipating it will clarify valuation and focus on Comcast's core connectivity and entertainment assets.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel, small-molecule therapeutics for the treatment of metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Aardvark Therapeutics Inc.

Aardvark Therapeutics Inc

Aardvark Therapeutics is trending as it halted its Phase 3 trial for ARD-101, its Prader-Willi Syndrome treatment, following reports of reversible cardiac safety signals. The community is actively discussing this significant setback, calling it a disaster and questioning the company's future in the competitive PWS treatment landscape.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is a hot topic amid mixed sentiment following its earnings report, which highlighted robust revenue growth and new defense contracts, but also confirmed a Neutron rocket launch delay into late in the year. While the community is enthusiastic about the company's expanding defense role and broader space industry tailwinds, concerns linger regarding the extended Neutron timeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Aldeyra Therapeutics CEO Highlights Reproxalap Ahead of March 16 FDA Decision at Oppenheimer Conference

Aldeyra Therapeutics (NASDAQ:ALDX) CEO Todd Brady provided an update on the company's late-stage ophthalmology programs and broader pipeline during a fireside chat at Oppenheimer's 36th Annual...

Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday

Aldeyra Therapeutics (NASDAQ:ALDX) will be releasing its Q4 2025 earnings before the market opens on Friday, February 27. (View Earnings Report at...

Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?

The consensus price target hints at a 79.3% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 200-Day Moving Average - Here's What Happened

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Pass Below 200-Day Moving Average - Time to Sell...

Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced...

Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Passes Above 50 Day Moving Average - Should You Sell?

Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above 50-Day Moving Average - Here's Why...

Wall Street Analysts Predict a 65.75% Upside in Aldeyra Therapeutics (ALDX): Here's  What You Should Know

The consensus price target hints at a 65.8% upside potential for Aldeyra Therapeutics (ALDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Are Medical Stocks Lagging  Aldeyra Therapeutics (ALDX) This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.

PFG Investments LLC Reduces Stock Position in Aldeyra Therapeutics, Inc. $ALDX

PFG Investments LLC cut its stake in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) by 74.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange...

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

ALDX
Aldeyra Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ALDX News

ALDXAldeyra Therapeutics Inc